NCT03451084 - A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

September 11, 2019

Study Completion Date

December 13, 2019

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

ASLAN003

Patients will be administered with the study drug, ASLAN003. The study drug is to be administered orally, QD or BID. It is recommended to administer the study drug with food or within 30 minutes after food intake.

Trial Locations (8)

40241

1 Site, Louisville

Unknown

1 Site, Albury

3 Sites, Darlinghurst

1 Site, Waratah

1 Site, Douglas

1 Site, Adelaide

3 Sites, Melbourne

3 Sites, Singapore